Clinical Trial: Ibrutinib with Pomalidomide and Dexamethasone for Relapsed/Refractory Myeloma Patients


Ibrutinib is a new drug being studied to treat myeloma and is a Bruton’s Tyrosine Kinase (BTK) Inhibitor. The drug targets BTK, an enzyme necessary for the development of fully functional B-cells. The BTK enzyme is known to be more prolific in cancerous B-cells.  Malignant myeloma cells have increased BTK expression compared to non-malignant cells, so blocking BTK activity in myeloma has been shown to inhibit growth of tumors and release of osteoclast-derived tumor growth factors. Ibrutinib has been studied since the 1990’s and has been used in many clinical trial in the last few years. 

A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)

The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:

  • Ibrutinib/pomalidomide/dex
  • Placebo/pomalidomide/dex

There are 5 locations for this trial. 

To find the clinical trial on SparkCures, click here:

Ibrutinib/Pom/Dex Clinical Trial


About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.


  1. Jenny,

    The article states that “Ibrutinib has been studied since the ninties…”, but the next sentence says “A Phase I clinical trial will study a new drug called ibrutinib…”.

    Is this a new drug?



Leave A Reply

Please enter the correct captcha code to verify that you are human.